Inside VIVEbiotech’s Work with Zelluna on TCR-NK Cell Therapy - Quiz - MDSpire

Inside VIVEbiotech’s Work with Zelluna on TCR-NK Cell Therapy

VIVEbiotech CEO Jon Alberdi lifts the lid on an eight-year collaboration focused on GMP lentiviral vectors for off-the-shelf solid tumor therapies

  • July 14, 2026

  • 4 min

Share

Original Source(s)

Inside VIVEbiotech’s Work with Zelluna on TCR-NK Cell Therapy

  • July 14, 2026

Related Content

Fibroblast activation protein inhibitor radiotheranostics for imaging activated tumor stroma and guiding radionuclide therapy

Diagnostic research in immune checkpoint inhibitor-related pneumonitis: a bibliometric analysis of research evolution, diagnostic focuses, and future priorities

T cell-mediated immune function in gastric cancer: a bibliometric overview of the last 20 years (2006-2025)